NASDAQ:LXEO • US52886X1072
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LEXEO THERAPEUTICS INC (LXEO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-01-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-18 | Raymond James | Initiate | Strong Buy |
| 2025-12-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-11-20 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-11-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-15 | Guggenheim | Initiate | Buy |
| 2025-10-07 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-10-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-31 | Oppenheimer | Initiate | Outperform |
| 2025-05-30 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-25 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-24 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-01-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 520K | 1.66M 219.23% | 650K -60.84% | -100.00% | 14.092M | -100.00% | 306.33M | 584.16M 90.70% | 803.14M 37.49% | 1.022B 27.25% | 1.193B 16.73% | ||||
| EBITDA YoY % growth | -4.59M | -50.63M -1,003.05% | -60.24M -18.98% | -73.44M -12.78% | -102M -55.10% | -112.2M -6.48% | -121.38M -8.18% | -143.82M -18.49% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.59M | -50.64M -1,003.27% | -60.51M -19.49% | -72.634M -13.23% | -109.29M -54.72% | -113.439M -7.02% | -117.428M -3.52% | -125.291M -6.70% | -51.006M 59.29% | 73.117M 243.35% | 291.43M 298.58% | 380.16M 30.45% | 543.27M 42.91% | 681.53M 25.45% | |
| Operating Margin | -882.69% | -3,050.60% | -9,309.23% | N/A | N/A | N/A | N/A | -889.09% | N/A | 23.87% | 49.89% | 47.33% | 53.16% | 57.13% | |
| EPS YoY % growth | N/A | N/A | N/A | -4.12 | -3.18 25.32% | -2.01 34.72% | -1.55 22.89% | -1.36 12.06% | -1.23 9.85% | 0.20 116.18% | 1.89 850.41% | 3.79 100.36% | 5.54 46.32% | 6.93 25.03% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 58.87% | -0.35 64.38% | -0.37 39.04% | -0.39 -18.34% | -0.41 -28.08% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -24.48M 3.55% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -25.616M 6.45% | -27.872M 17.55% | -29.085M 5.22% | -30.654M -41.60% | -32.045M -25.10% |
All data in USD
17 analysts have analysed LXEO and the average price target is 20.03 USD. This implies a price increase of 260.24% is expected in the next year compared to the current price of 5.56.
The consensus EPS estimate for the next earnings of LEXEO THERAPEUTICS INC (LXEO) is -0.32 USD and the consensus revenue estimate is 0 USD.